Tag: radiotherapy

Andarix Pharmaceuticals CEO to Present on Targeted Radiometal Therapeutics for Lung Cancer at International Symposium on Bioorganometallic Chemistry 2025

Aug 21, 2025

—

by

cadams

in Uncategorized

conference, international, lung cancer, oncology, personalized medicine, radiotherapy, symposiuim, targeted therapy

Presentation underscores Andarix’s leadership in advancing radiometal-based cancer therapeutics and highlights partnering and investment opportunities in a rapidly growing field. FOR IMMEDIATE RELEASE August 25, 2025 Contact: Andarix Pharmaceuticals 617-957-9858 info@andarix.com Boston, MA – August 25, 2025 – Andarix Pharmaceuticals, a clinical‑stage biopharmaceutical company developing next‑generation targeted radiotherapeutics for oncology, today announced that Chief Executive Officer Chris…
Pioneering Targeted Therapies: Andarix Presents New Data on Radiopharmaceutical Innovations for Lung and Pancreatic Cancer

Jul 29, 2025

—

by

cadams

in Uncategorized

cancer, conference, oncology, pancreatic cancer, personalized medicine, radiotherapy, targeted therapy, technology

FOR IMMEDIATE RELEASE July 29, 2025 Contact: Andarix Pharmaceuticals 617-957-9858 info@andarix.com Driving New Partnerships and Investment Opportunities in Precision Oncology Radiopharmaceuticals Boston — At the 4th Targeted Radiopharmaceuticals Summit US, Andarix Pharmaceuticals is showcasing its pioneering targeted radiopharmaceutical technology for treating lung and pancreatic cancer. Company leadership is presenting recent data demonstrating how Andarix’s proprietary…
Andarix Pharmaceuticals Awarded Trademark for Tozaride by the US Patent and Trademark Office

Apr 26, 2019

—

by

cadams

in Article

lung cancer, radiotherapy, sclc, small cell lung cancer, targeted therapy

Andarix Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it has been granted the US trademark for Tozaride by the United States Patent and Trademark Office.
Andarix Pharmaceuticals to Present at Neosynth Breast Cancer Conference

Apr 25, 2019

—

by

cadams

in Article

breast cancer, conference, radiotherapy, targeted therapy

Andarix Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it will present at the Neosynth Breast Cancer Conference in Boston MA on April 24-25th 2019. The presentation will address the ability of theranostic technology to provide personalized medicine to diagnose and treat breast cancer. The three main types…
Andarix Pharmaceuticals to Present Lung Cancer Clinical Trial Results at the Society of Nuclear Medicine Meeting

Oct 31, 2018

—

by

cadams

in Article

clinical study, conference, lung cancer, oncology, radiotherapy, targeted therapy

ANDARIX Pharmaceuticals, a leader in the discovery and development of targeted peptide therapy for cancer announced today that it will present the results of its latest clinical trial in lung cancer patients. The trial focused on the administration of Tozaride, the company’s lead candidate in neuroendocrine lung cancer patients. The abstract is entitled “Targeted Clinical Study…
Andarix Pharmaceuticals to Present at the Rare Disease Innovation Summit

Jul 19, 2018

—

by

cadams

in Article

oncology, radiotherapy, targeted therapy

Andarix Pharmaceuticals, a clinical stage company aimed at developing targeted peptide therapies for hard to treat cancers, announced today that its Chief Executive Officer, Chris Adams, will present at the Rare Disease Innovation Summit set to take place in Cambridge , MA June 19-20.
Andarix Pharmaceuticals to Present at Regulatory Pathways Summit Conference

Feb 12, 2018

—

by

cadams

in Article

lung cancer, orphan drug, personalized medicine, radiotherapy, sclc, small cell lung cancer, targeted therapy

Andarix Pharmaceuticals, a clinical stage company, developing a targeted peptide therapy for small cell lung cancer announced that its Chief Executive Officer, Chris Adams, will present at the Innovative Regulatory Pathways Summit in Washington, DC. January 29-30, 2018.
A Billion Dollar Drug Using a Virtual Business Model

Oct 13, 2017

—

by

cadams

in Article

oncology, personalized medicine, radiotherapy, targeted therapy

Chris Adams, CEO, Andarix, explains how industry can leverage technology to make the drug development process more efficient
Andarix Pharmaceuticals Selected to Present at Lung Cancer Summit in Boston, MA

Sep 26, 2017

—

by

cadams

in Article

lung cancer, radiotherapy, sclc, targeted therapy

Andarix Pharmaceuticals, a clinical stage company, developing a targeted peptide therapy for small cell lung cancer announced that its Chief Executive Officer, Chris Adams, will present at the Precision Lung Cancer Summit in Boston, Massachusetts July 25-26, 2017. Conference location and agenda information are available at the Precision Lung Cancer Conference.
Andarix Pharmaceuticals and Wuxi Fortune Pharmaceuticals Sign Drug Deal for China Market

Sep 26, 2017

—

by

cadams

in Article

lung cancer, radiotherapy, targeted therapy

Andarix Pharmaceuticals Inc, a clinical stage company, and Wuxi Fortune Pharmaceuticals announced today the signing of an agreement to develop and commercialize a drug to treat lung and other cancers. As part of the agreement Wuxi Fortune will have certain rights to the China market for Tozaride, a targeted peptide therapy. Wuxi Fortune and Andarix…